Medical Devices Stocks in the US

The largest Medical Devices stocks in the US by market value are Abbott Laboratories ($190.4B), Medtronic plc ($124.7B) and Stryker Corporation ($124.1B), at prices of 6 Nov 2026.

• Abbott Laboratories: $109.95 | market value $190.4B | P/E 36.6
• Medtronic plc: $101.88 | market value $124.7B | P/E 20.9
• Stryker Corporation: $325.92 | market value $124.1B | P/E 29.2
• Boston Scientific Corporation: $42.77 | market value $62.0B | P/E 18.1
• Edwards Lifesciences Corporation: $102.12 | market value $58.7B | P/E 48.7
• GE HealthCare Technologies Inc.: $82.39 | market value $37.3B | P/E 13.7
• Koninklijke Philips N.V.: $30.34 | market value $29.6B | P/E 22.1
• DexCom, Inc.: $79.43 | market value $29.6B | P/E 32.9
• STERIS plc: $252.45 | market value $24.5B | P/E 24.8
• Zimmer Biomet Holdings, Inc.: $105.54 | market value $20.0B | P/E 22.1

The other 20 Medical Devices companies are in the full list below.

Share price | market value | P/E, biggest first. Prices and market values as of 6 Nov 2026; ratios as in the score list below.

Ranked by the 4-Factor Sector Score (growth & earnings 35, capital efficiency 25, valuation 20, relative strength 20). Prices as of 6 Nov 2026.

The largest 15 of 30 listed US Medical Devices companies are named here; all 30 are ranked in the scorecard. Every figure is equal-weighted across those companies and carries its own as-of date. One large company cannot set the reading.

1. Abbott Laboratories$190.4B
2. Medtronic plc$124.7B
3. Stryker Corporation$124.1B
4. Boston Scientific Corporation$62.0B
5. Edwards Lifesciences Corporation$58.7B
6. GE HealthCare Technologies Inc.$37.3B
7. Koninklijke Philips N.V.$29.6B
8. DexCom, Inc.$29.6B
9. STERIS plc$24.5B
10. Zimmer Biomet Holdings, Inc.$20.0B
11. Glaukos Corporation$13.3B
12. Smith & Nephew plc$13.0B
13. Penumbra, Inc.$12.6B
14. Bio-Rad Laboratories, Inc.$10.3B
15. Insulet Corporation$10.2B

The remaining 15 Medical Devices companies are named and ranked in the scorecard.

75 Medical Devices companies in the Medical Devices industry group (every listed company) have a page on Sector Alpha, by market value as of 6 November 2026, and all 75 are listed below, largest first. The largest is Abbott Laboratories ($190.4 billion) and the smallest with a market value is Perspective Therapeutics, Inc.

Download all 75 Medical Devices companies (CSV)

The line below covers up to 5.2 years and opens on the 5Y view; the buttons cut it shorter. Over the last two years (104 weeks) this industry is 9% ahead of S&P 500. Earnings across its companies grew 16% on average over the last four reported quarters. It has been ahead of S&P 500 on a rolling three-month view for 20 weeks running.

36 of 72 companies ahead of S&P 500 by 5% or more over three months. 5 are 20% or more behind over a year while earnings grew 20% or more.

Ahead of S&P 500 on the three-month view for 20 weeks running; 42 of the 71 companies in the industry index above their 200-day average (8 more than four weeks earlier); 36 of those 72 ahead of S&P 500 by 5% or more over three months (11 more than four weeks earlier); earnings rising at 47 of the 68 that report earnings.

Ahead of S&P 500 for 20 weeks running and +17.4% over a year, with 25 → 36 of 72 stocks participating. Earnings confirming, 47 of 68 members have higher trailing twelve-month earnings than a year ago.

Both lines start at 200 in the same week, so the gap between them tells the story: the industry line is an equal-weighted index of its 72 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member set to 100 at the start and the industry taking the middle value, so a price line pulling away from flat bars means the market is paying more for the same earnings. A bar turns grey when that figure is lower than the quarter before. The rules are fixed and the same everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover or tap any point to read both values and the gap.

Medical Devices has done better than the S&P 500 by 14.9% over the last 52 weeks. Over 13 weeks the gap is a lead of 9.4%. Glaukos Corporation is the strongest against the sector itself at +44.3%.

Medical Devices has done better than the S&P 500 by 14.9% over 52 weeks and by 9.4% over 13 weeks. 19 of 30 companies we track are beating the S&P 500 on relative strength (how a share price has done against the index over recent months), and 12 of 30 are ahead of the industry itself.

A score that ranks each company against the others in its industry. The four parts shown always add up to the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or old evidence affects only its own part, never as a hidden adjustment.

Insulet Corporation has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 81.1% evidence confidence.

Haemonetics Corporation scores well on valuation against its peers or its own history, but its earnings have not yet improved enough to back that up.

Ranked last: too little evidence (1 company)

Under 60% of the evidence behind this score is available, so it ranks after every company above, whatever the score.

Butterfly Network, Inc. has the strongest one-year price move in Medical Devices at +185.7%. Glaukos Corporation leads on relative strength against the S&P 500, at +60.9%. 19 of 30 companies we track are ahead of the index on that measure. Every line covers 313 weekly closes through 6 November 2026.

Price and relative strength

Price · same starting point: Every company, the sector's own index and S&P 500 all start level on the left edge of the window, so only the distance between the lines counts: the highest line has risen the most since then, and the chart at the top of this page is drawn the same way. It opens on one year; the buttons beside it stretch that to three or five.

RS vs S&P 500: How far ahead of or behind S&P 500 each company has been running, measured against its own recent average of that comparison, so the flat line at zero IS S&P 500: above it the company is beating the market, below it the market is beating the company. It opens on one year.

RS vs sector: The same measure taken against Medical Devices itself instead of the whole market, so the flat line at zero is the sector: above it the company is beating its own peers, which is the sharper test of the two. It opens on one year.

Biggest one-year moves

Strongest against S&P 500

Strongest against the sector itself

Abbott Laboratories has the highest Revenue among the 30 Medical Devices companies compared here, at $48,229 million. Medtronic plc is next at $37,541 million. Glaukos Corporation has the highest Revenue growth at 47%, so level and change sit with different companies. 27 of 30 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Abbott Laboratories is the largest at $48,229 million, 28.5% ahead of Medtronic plc. Glaukos Corporation's growth is 47% from a $691 million base, with 19 reported quarters out of the last 20. Fast growth from a smaller base is not yet the same as proven size.

What this means: Abbott Laboratories is the size to compare against; Glaukos Corporation is the one growing fastest. The faster grower has to keep that growth and turn it into margin and returns before it counts as more than a fast start.

This conclusion weakens if: Abbott Laboratories's growth falls below Glaukos Corporation's for two consecutive comparable reports while operating margin also compresses.

Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.

Revenue · company comparison

Revenue · largest

Revenue growth · fastest growers

All-company data · latest reported quarter

In every all-company table on this page, each figure is the company’s latest single reported quarter. The rankings above them use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.

Revenue shows both size and speed. A large company can absorb shocks and pay for wide distribution; faster growth can mean market-share gains, new capacity or stronger demand. The best sign is usually growth that lasts without hurting margins and returns.

Edwards Lifesciences Corporation has the highest OPM among the 30 Medical Devices companies compared here, at 30.2%. DexCom, Inc. is next at 24.3%. Butterfly Network, Inc. has the highest Margin change at +40.5 percentage points, so level and change sit with different companies. 30 of 30 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Edwards Lifesciences Corporation leads opm at 30.2%; Butterfly Network, Inc. leads margin change at +40.5 percentage points.

What this means: Edwards Lifesciences Corporation sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current margin change signal.

Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.

Operating margin · company comparison

OPM · highest

Margin change · fastest expanders

All-company data · latest reported quarter

Medtronic plc has the highest Net profit among the 30 Medical Devices companies compared here, at $5,231 million. Abbott Laboratories is next at $4,677 million. Inspire Medical Systems, Inc. has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.

What the numbers say: Medtronic plc earns the most, $5,231 million of profit over the last 12 months, 11.8% above Abbott Laboratories. Inspire Medical Systems, Inc. shows at least 100% on the scoring scale (129.6% in full) growth from a profit base of $101 million. A fast rate from a small base matters less than a large profit that keeps coming.

What this means: Medtronic plc sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.

Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.

Net profit · company comparison

Net profit · largest

Profit growth · fastest growers

All-company data · latest reported quarter

DexCom, Inc. has the highest ROCE among the 30 Medical Devices companies compared here, at 30.7%. Insulet Corporation is next at 22.6%. Establishment Labs Holdings Inc. has the highest ROCE change at +14.1 percentage points, so level and change sit with different companies. 30 of 30 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: DexCom, Inc. leads ROCE at 30.7%, 8.1 percentage points above Insulet Corporation. A high return reported once may be one good year; a high return reported year after year shows a lasting business.

What this means: DexCom, Inc. sets the level to compare against; the company improving fastest needs another report to confirm the change.

This conclusion weakens if: The next two comparable reports reverse the current roce change signal.

ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.

Return on capital · company comparison

ROCE · highest

ROCE change · fastest improvers

All-company data · latest reported quarter

Insulet Corporation has the lowest PEG among the 30 Medical Devices companies compared here, at 0.4×. TransMedics Group, Inc. is next at 0.43×. Bruker Corporation has the lowest P/E at −151×, so level and change sit with different companies. 16 of 30 companies report a comparable reading, the latest through Sep 2026.

What the numbers say: Insulet Corporation has the lowest comparable PEG at 0.4×, 7% below TransMedics Group, Inc. That would need today's multiple, the company's own history and steady growth to agree.

What this means: A low valuation is a reason to look closer at the business, not a conclusion on its own.

This conclusion weakens if: The next two comparable reports reverse the current p/e signal.

PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is worked out the same way every time, as the P/E on the last 12 months of reported earnings divided by that growth rate, never on expected earnings. On Indian companies it is shown only where the two data feeds agreed. Where any of that fails the ratio is left out rather than printed: a P/E divided by a loss, or by growth measured off a tiny base, is a number that looks precise and means nothing.

Valuation · company comparison